Base de dados : MEDLINE
Pesquisa : D12.776.395.550.550.249 [Categoria DeCS]
Referências encontradas : 879 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 88 ir para página                         

  1 / 879 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776018
[Au] Autor:Vartanian A; Baryshnikova M; Burova O; Afanasyeva D; Misyurin V; Belyаvsky A; Shprakh Z
[Ad] Endereço:Department of Experimental Diagnosis and Therapy of Tumors, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
[Ti] Título:Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
[So] Source:Melanoma Res;27(1):8-16, 2017 Feb.
[Is] ISSN:1473-5636
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The increasing incidence of melanoma makes this cancer an important public health problem. Therapeutic resistance is still a major obstacle to the therapy of patients with metastatic melanomas. The aim of this study was to develop the melanoma cell line resistant to DNA-alkylating agents and to elucidate the mechanisms involved in acquired drug resistance. We established a unique melanoma subline Mel MeR resistant to DNA-alkylating drug aranoza by continuous stepwise selection of the Mel Me/WT cell line with increasing concentrations of this drug. Mel MeR cells were also cross-resistant to streptozotocin or cisplatin. Here, we show that aranoza-resistant melanoma cells modulate the ABC transporter activity, upregulate the expression of PRAME, adopt a vascular-related phenotype and engage in vasculogenic mimicry. LCS1269, a vasculogenic mimicry low-molecular-weight inhibitor, reverses the sensitivity of resistant melanoma cells to DNA-damaging agents. In this study, we provide experimental evidence that LCS1269 might be considered as a new potential anticancer agent capable of overcoming multidrug resistance for DNA-damaging agents in melanoma.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/farmacologia
Carbazóis/farmacologia
Linhagem Celular Tumoral
Resistência a Medicamentos Antineoplásicos
Glicosídeos/farmacologia
Melanoma/tratamento farmacológico
Melanoma/metabolismo
Metilnitrosoureia/análogos & derivados
Neovascularização Patológica/prevenção & controle
[Mh] Termos MeSH secundário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo
Antígenos de Neoplasias/genética
Apoptose/efeitos dos fármacos
Antígeno CD24/metabolismo
Resistência a Medicamentos Antineoplásicos/genética
Endoglina/metabolismo
Corantes Fluorescentes/metabolismo
Expressão Gênica/efeitos dos fármacos
Seres Humanos
Receptores de Hialuronatos/metabolismo
Molécula 1 de Adesão Intercelular/metabolismo
Masculino
Melanoma/irrigação sanguínea
Melanoma/genética
Metilnitrosoureia/farmacologia
Meia-Idade
Proteínas de Neoplasias/genética
Células-Tronco Neoplásicas/metabolismo
Proteínas Nucleares/genética
Fenótipo
Fosfoproteínas Fosfatases/genética
Proteínas Proto-Oncogênicas c-kit/metabolismo
Rodamina 123/metabolismo
Tetraspanina 30/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABCB5 protein, human); 0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Antigens, Neoplasm); 0 (Antineoplastic Agents, Alkylating); 0 (CD24 Antigen); 0 (CD24 protein, human); 0 (CD44 protein, human); 0 (CD63 protein, human); 0 (Carbazoles); 0 (ENG protein, human); 0 (Endoglin); 0 (Fluorescent Dyes); 0 (GAGE1 protein, human); 0 (Glycosides); 0 (Hyaluronan Receptors); 0 (LCS1269); 0 (Neoplasm Proteins); 0 (Nuclear Proteins); 0 (PRAME protein, human); 0 (Tetraspanin 30); 0 (aranoza); 126547-89-5 (Intercellular Adhesion Molecule-1); 1N3CZ14C5O (Rhodamine 123); 684-93-5 (Methylnitrosourea); EC 2.7.10.1 (Proto-Oncogene Proteins c-kit); EC 3.1.3.16 (CTDSP1 protein, human); EC 3.1.3.16 (Phosphoprotein Phosphatases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1097/CMR.0000000000000308


  2 / 879 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449081
[Au] Autor:Luedtke BE; Mahapatra S; Lutter EI; Shaw EI
[Ad] Endereço:Department of Biology, University of Nebraska at Kearney, Kearney, NE 68849, USA.
[Ti] Título:The Coxiella Burnetii type IVB secretion system (T4BSS) component DotA is released/secreted during infection of host cells and during in vitro growth in a T4BSS-dependent manner.
[So] Source:Pathog Dis;75(4), 2017 Jun 01.
[Is] ISSN:2049-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Coxiella burnetii is a Gram-negative intracellular pathogen and is the causative agent of the zoonotic disease Q fever. To cause disease, C. burnetii requires a functional type IVB secretion system (T4BSS) to transfer effector proteins required for the establishment and maintenance of a membrane-bound parasitophorous vacuole (PV) and further modulation of host cell process. However, it is not clear how the T4BSS interacts with the PV membrane since neither a secretion pilus nor an extracellular pore forming apparatus has not been described. To address this, we used the acidified citrate cysteine medium (ACCM) along with cell culture infection and immunological techniques to identify the cellular and extracellular localization of T4BSS components. Interestingly, we found that DotA and IcmX were secreted/released in a T4BSS-dependent manner into the ACCM. Analysis of C. burnetii-infected cell lines revealed that DotA colocalized with the host cell marker CD63 (LAMP3) at the PV membrane. In the absence of bacterial protein synthesis, DotA also became depleted from the PV membrane. These data are the first to identify the release/secretion of C. burnetii T4BSS components during axenic growth and the interaction of a T4BSS component with the PV membrane during infection of host cells.
[Mh] Termos MeSH primário: Proteínas de Bactérias/secreção
Coxiella burnetii/crescimento & desenvolvimento
Coxiella burnetii/metabolismo
Interações Hospedeiro-Patógeno
Sistemas de Secreção Tipo IV/metabolismo
Vacúolos/microbiologia
[Mh] Termos MeSH secundário: Proteínas de Bactérias/análise
Tetraspanina 30/análise
Vacúolos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (CD63 protein, human); 0 (Tetraspanin 30); 0 (Type IV Secretion Systems)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1093/femspd/ftx047


  3 / 879 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775867
[Au] Autor:Fischer J; Eberlein B; Hilger C; Eyer F; Eyerich S; Ollert M; Biedermann T
[Ad] Endereço:Department of Dermatology, Faculty of Medicine, Eberhard Karls University Tuebingen, Tuebingen, Germany.
[Ti] Título:Alpha-gal is a possible target of IgE-mediated reactivity to antivenom.
[So] Source:Allergy;72(5):764-771, 2017 May.
[Is] ISSN:1398-9995
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Antivenoms are mammalian immunoglobulins with the ability to neutralize snake venom components and to mitigate the progression of toxic effects. Immediate hypersensitivity to antivenoms often occurs during the first administration of these heterologous antibodies. A comparable clinical situation occurred after introduction of cetuximab, a chimeric mouse-human antibody, for cancer treatment. The carbohydrate epitope galactose-alpha-1,3-galactose, located on the Fab region of cetuximab, was identified as the target responsible for IgE reactivity. OBJECTIVE: To investigate whether serum IgE antibodies directed to the α-gal epitope are associated with hypersensitivity to equine antivenoms. METHODS: Antivenoms were screened for α-gal epitopes via immunoblot and in comparison with cetuximab and pork kidney by IgE reactivity assays. Basophil activation tests were used to investigate reactivity to antivenoms in samples from 20 patients with specific IgE antibodies to α-gal and 10 controls. Additional IgE detection, IgE inhibition, ImmunoCAP inhibition, and skin prick tests were performed using samples from selected patients. RESULTS: Both antivenoms and cetuximab induced positive skin prick test results in patients with sIgE to α-gal. Alpha-gal epitopes were detected by immunoblotting on antivenoms. Measurements of IgE reactivity and ImmunoCAP inhibition indicated that the antivenoms contained lower α-gal contents than cetuximab. Deglycosylation assays and IgE inhibition tests confirmed that IgE-mediated reactivity to antivenom is associated with α-gal. Antivenoms, pork kidney, and cetuximab activated basophils from patients with IgE to α-gal. CONCLUSION: Alpha-gal is a potential target of IgE-mediated reactivity to equine antivenom and a possible cause of the high incidence of hypersensitivity reactions during the first application of equine antivenom.
[Mh] Termos MeSH primário: Antivenenos/imunologia
Hipersensibilidade Imediata/imunologia
Imunoglobulina E/imunologia
alfa-Galactosidase/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Animais
Basófilos/imunologia
Basófilos/metabolismo
Biomarcadores
Cetuximab/efeitos adversos
Relação Dose-Resposta Imunológica
Epitopos/imunologia
Feminino
Cavalos
Seres Humanos
Hipersensibilidade Imediata/diagnóstico
Hipersensibilidade Imediata/metabolismo
Masculino
Meia-Idade
Testes Cutâneos
Tetraspanina 30/metabolismo
Tireoglobulina/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antivenins); 0 (Biomarkers); 0 (Epitopes); 0 (Tetraspanin 30); 37341-29-0 (Immunoglobulin E); 9010-34-8 (Thyroglobulin); EC 3.2.1.22 (alpha-Galactosidase); PQX0D8J21J (Cetuximab)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171207
[Lr] Data última revisão:
171207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1111/all.13073


  4 / 879 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29023592
[Au] Autor:Niu Z; Pang RTK; Liu W; Li Q; Cheng R; Yeung WSB
[Ad] Endereço:Department of Obstetrics and Gynecology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
[Ti] Título:Polymer-based precipitation preserves biological activities of extracellular vesicles from an endometrial cell line.
[So] Source:PLoS One;12(10):e0186534, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Extracellular vesicles (EVs) are membrane-bound vesicles released by cells and act as media for transfer of proteins, small RNAs and mRNAs to distant sites. They can be isolated by different methods. However, the biological activities of the purified EVs have seldom been studied. In this study, we compared the use of ultracentrifugation (UC), ultra-filtration (UF), polymer-based precipitation (PBP), and PBP with size-based purification (PBP+SP) for isolation of EVs from human endometrial cells and mouse uterine luminal fluid (ULF). Electron microscopy revealed that the diameters of the isolated EVs were similar among the tested methods. UF recovered the highest number of EVs followed by PBP, while UC and PBP+SP were significantly less efficient (P<0.05). Based on the number of EVs-to-protein ratios, PBP had the least protein contamination, significantly better than the other methods (P<0.05). All the isolated EVs expressed exosome-enriched proteins CD63, TSG101 and HSP70. Incubation of the trophoblast JEG-3 cells with an equal amount of the fluorescence-labelled EVs isolated by the studied methods showed that many of the PBP-EVs treated cells were fluorescence positive but only a few cells were labelled in the UC- and UF-EVs treated groups. Moreover, the PBP-EVs could transfer significantly more miRNA to the recipient cells than the other 3 methods (P<0.05). The PBP method could isolate EVs from mouse ULF; the diameter of the isolated EVs was 62±19 nm and expressed CD63, TSG101 and HSP70 proteins. In conclusion, PBP could best preserve the activities of the isolated EVs among the 4 methods studied and was able to isolate EVs from a small volume of sample. The simple setup and low equipment demands makes PBP the most suitable method for rapid EV assessment and isolation of EVs in clinical and basic research settings.
[Mh] Termos MeSH primário: Vesículas Extracelulares/metabolismo
Polímeros/química
[Mh] Termos MeSH secundário: Compostos de Anilina/farmacologia
Animais
Compostos de Benzilideno/farmacologia
Blastocisto/citologia
Blastocisto/metabolismo
Linhagem Celular
Precipitação Química
Técnicas de Cocultura
Proteínas de Ligação a DNA/metabolismo
Neoplasias do Endométrio/metabolismo
Neoplasias do Endométrio/patologia
Complexos Endossomais de Distribuição Requeridos para Transporte/metabolismo
Exossomos/efeitos dos fármacos
Exossomos/metabolismo
Vesículas Extracelulares/ultraestrutura
Feminino
Proteínas de Choque Térmico HSP70/metabolismo
Seres Humanos
Camundongos
MicroRNAs/metabolismo
Microscopia Eletrônica
Microscopia de Fluorescência
Tetraspanina 30/metabolismo
Fatores de Transcrição/metabolismo
Trofoblastos/citologia
Trofoblastos/metabolismo
Ultracentrifugação
Ultrafiltração
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aniline Compounds); 0 (Benzylidene Compounds); 0 (DNA-Binding Proteins); 0 (Endosomal Sorting Complexes Required for Transport); 0 (GW 4869); 0 (HSP70 Heat-Shock Proteins); 0 (MicroRNAs); 0 (Polymers); 0 (Tetraspanin 30); 0 (Transcription Factors); 0 (Tsg101 protein)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171013
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186534


  5 / 879 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28707662
[Au] Autor:Starodubova ES; Kuzmenko YV; Latanova AA; Preobrazhenskaya OV; Karpov VL
[Ad] Endereço:Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
[Ti] Título:[C-terminal lysosome targeting domain of CD63 modifies cellular localization of rabies virus glycoprotein].
[So] Source:Mol Biol (Mosk);51(3):460-463, 2017 May-Jun.
[Is] ISSN:0026-8984
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The glycoprotein of rabies virus is the central antigen elicited the immune response to infection; therefore, the majority of developing anti-rabies vaccines are based on this protein. In order to increase the efficacy of DNA immunogen encoding rabies virus glycoprotein, the construction of chimeric protein with the CD63 domain has been proposed. The CD63 is a transmembrane protein localized on the cell surface and in lysosomes. The lysosome targeting motif GYEVM is located at its C-terminus. We used the domain that bears this motif (c-CD63) to generate chimeric glycoprotein in order to relocalize it into lysosomes. Here, it was shown that, in cells transfected with plasmid that encodes glycoprotein with c-CD63 motif at the C-terminus, the chimeric protein was predominantly observed in lysosomes and at the cell membrane where the unmodified glycoprotein is localized in the endoplasmic reticulum and at the cell surface. We suppose that current modification of the glycoprotein may improve the immunogenicity of anti-rabies DNA vaccines due to more efficient antibody production.
[Mh] Termos MeSH primário: Glicoproteínas/genética
Vacinas Antirrábicas/genética
Raiva/imunologia
Tetraspanina 30/genética
[Mh] Termos MeSH secundário: Glicoproteínas/imunologia
Células HeLa
Seres Humanos
Lisossomos/genética
Lisossomos/imunologia
Domínios Proteicos/genética
Domínios Proteicos/imunologia
Raiva/prevenção & controle
Raiva/virologia
Vacinas Antirrábicas/imunologia
Vírus da Raiva/imunologia
Vírus da Raiva/patogenicidade
Proteínas Recombinantes de Fusão/genética
Proteínas Recombinantes de Fusão/imunologia
Tetraspanina 30/imunologia
Vacinas de DNA/imunologia
Vacinas de DNA/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glycoproteins); 0 (Rabies Vaccines); 0 (Recombinant Fusion Proteins); 0 (Tetraspanin 30); 0 (Vaccines, DNA)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE
[do] DOI:10.7868/S0026898417020203


  6 / 879 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28602860
[Au] Autor:Hassuna NA; Monk PN; Ali F; Read RC; Partridge LJ
[Ad] Endereço:Dept. Medical Microbiology and Immunology, Faculty of Medicine, Minia University, Minia, Egypt. Electronic address: nohaanwar@mu.edu.eg.
[Ti] Título:A role for the tetraspanin proteins in Salmonella infection of human macrophages.
[So] Source:J Infect;75(2):115-124, 2017 Aug.
[Is] ISSN:1532-2742
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Infected macrophages play a role in the dissemination of Salmonella and may serve as a reservoir of infection in asymptomatic carriers. However, relatively little is known about the early molecular interactions of the bacteria with these cells. We have recently shown that members of the tetraspanin family of membrane proteins are involved in the initial adhesion of a range of bacteria to host cells. This study investigated the role of tetraspanins in Salmonella enterica subsp. enterica serovar Typhimurium (S. Typhimurium) infection of human monocyte-derived macrophages (MDM). METHODS: The role of tetraspanins was studied by the use of tetraspanins recombinant proteins as well as monoclonal antibodies targeted against different tetraspanins. Knockdown of the tetraspanin CD63 was carried out by siRNA to further study the role of CD63 in Salmonella uptake. RESULTS: Recombinant proteins representing the large extracellular domains of tetraspanins inhibited binding of S. Typhimurium to human MDM by ∼50%, whereas tetraspanin-specific antibodies showed varying effects, with some enhancing (anti-CD37) and some inhibiting (anti-CD81, anti-CD63) binding. Inhibition of the S. Typhimurium-MDM interaction by anti-CD63 mAb appeared to be mediated by antibody induced internalization, suggesting that surface expression of CD63 is required for S. Typhimurium binding. Knockdown of CD63 in human MDM using siRNA greatly reduced S. Typhimurium binding, confirming the importance of CD63. However, ectopic expression of CD63 in the non-phagocytic cell line HEK293 was insufficient to mediate bacterial binding. CONCLUSION: Bacterial adhesion is the first step in infection by pathogens that invade and replicate within host cells. Taken together, the results here describe a role for tetraspanins in binding of S. Typhimurium to human macrophages and highlight the particular importance of CD63 in this process.
[Mh] Termos MeSH primário: Aderência Bacteriana/imunologia
Macrófagos/imunologia
Infecções por Salmonella/imunologia
Salmonella typhimurium/patogenicidade
Tetraspanina 30/metabolismo
[Mh] Termos MeSH secundário: Células Cultivadas
Técnicas de Silenciamento de Genes
Células HEK293
Seres Humanos
Infecções por Salmonella/microbiologia
Tetraspanina 30/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD63 protein, human); 0 (Tetraspanin 30)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE


  7 / 879 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28507029
[Au] Autor:Kanuma T; Yamamoto T; Kobiyama K; Moriishi E; Masuta Y; Kusakabe T; Ozasa K; Kuroda E; Jounai N; Ishii KJ
[Ad] Endereço:Laboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan.
[Ti] Título:CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8 T Cell Responses.
[So] Source:J Immunol;198(12):4707-4715, 2017 Jun 15.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:DNA vaccines are attractive immunogens for priming humoral and cellular immune responses to the encoded Ag. However, their ability to induce Ag-specific CD8 T cell responses requires improvement. Among the strategies for improving DNA vaccine immunogenicity are booster vaccinations, alternate vaccine formulations, electroporation, and genetic adjuvants, but few, such as extracellular vesicles (EVs), target natural Ag delivery systems. By focusing on CD63, a tetraspanin protein expressed on various cellular membranes, including EVs, we examined whether a DNA vaccine encoding an Ag fused to CD63 delivered into EVs would improve vaccine immunogenicity. In vitro transfection with plasmid DNA encoding an OVA Ag fused to CD63 (pCD63-OVA) produced OVA-carrying EVs. Immunizations with the purified OVA-carrying EVs primed naive mice to induce OVA-specific CD4 and CD8 T cells, whereas immunization with EVs purified from cells transfected with control plasmids encoding OVA protein alone or a calnexin-OVA fusion protein delivered into the endoplasmic reticulum failed to do so. Vaccinating mice with pCD63-OVA induced potent Ag-specific T cell responses, particularly those from CD8 T cells. CD63 delivery into EVs led to better CD8 T cell responses than calnexin delivery into the endoplasmic reticulum. When we used a mouse tumor implantation model to evaluate pCD63-OVA as a therapeutic vaccine, the EV-delivered DNA vaccination significantly inhibited tumor growth compared with the control DNA vaccinations. These results indicate that EV Ag delivery via DNA vaccination offers a new strategy for eliciting strong CD8 T cell responses to the encoded Ag, making it a potentially useful cancer vaccine.
[Mh] Termos MeSH primário: Linfócitos T CD8-Positivos/imunologia
Vesículas Extracelulares/imunologia
Ativação Linfocitária
Tetraspanina 30/imunologia
Vacinas de DNA/imunologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/administração & dosagem
Animais
Apresentação do Antígeno/imunologia
Linfócitos T CD4-Positivos/imunologia
Vacinas Anticâncer/imunologia
Feminino
Imunidade Celular
Imunização Secundária
Imunogenicidade da Vacina
Camundongos
Camundongos Endogâmicos C57BL
Ovalbumina/imunologia
Tetraspanina 30/genética
Vacinas de DNA/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Cancer Vaccines); 0 (Tetraspanin 30); 0 (Vaccines, DNA); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170517
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1600731


  8 / 879 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28414061
[Au] Autor:Frischmeyer-Guerrerio PA; Masilamani M; Gu W; Brittain E; Wood R; Kim J; Nadeau K; Jarvinen KM; Grishin A; Lindblad R; Sampson HA
[Ad] Endereço:Laboratory of Allergic Diseases, Food Allergy Research Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
[Ti] Título:Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.
[So] Source:J Allergy Clin Immunol;140(4):1043-1053.e8, 2017 Oct.
[Is] ISSN:1097-6825
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy improved safety, but no significant clinical benefit was detected. OBJECTIVE: We sought to investigate mechanisms by which omalizumab modulates immunity in the context of OIT and to identify baseline biomarkers that predict subgroups of patients most likely to benefit from omalizumab. METHODS: Blood was obtained at baseline and multiple time points during a placebo-controlled trial of OIT for milk allergy in which subjects were randomized to receive omalizumab or placebo. Immunologic outcomes included measurement of basophil CD63 expression and histamine release and casein-specific CD4 regulatory T-cell proliferation. Biomarkers were analyzed in relationship to measurements of safety and efficacy. RESULTS: Milk-induced basophil CD63 expression was transiently reduced in whole blood samples from both omalizumab- and placebo-treated subjects. However, IgE-dependent histamine release increased in washed cell preparations from omalizumab- but not placebo-treated subjects. No increase in regulatory T-cell frequency was evident in either group. Subjects with lower rates of adverse reactions, regardless of arm, experienced better clinical outcomes. Pre-OIT basophil reactivity positively associated with occurrence of symptoms during OIT, whereas the baseline milk IgE/total IgE ratio correlated with the likelihood of achieving sustained unresponsiveness. A combination of baseline basophil and serologic biomarkers defined a subset of patients in which adjunctive therapy with omalizumab was associated with attainment of sustained unresponsiveness and a reduction in adverse reactions. CONCLUSIONS: Combining omalizumab therapy with milk OIT led to distinct alterations in basophil reactivity but not T-cell responses. Baseline biomarkers can identify subjects most likely to benefit from adjunctive therapy with omalizumab.
[Mh] Termos MeSH primário: Antialérgicos/uso terapêutico
Basófilos/imunologia
Dessensibilização Imunológica/métodos
Hipersensibilidade a Leite/terapia
Omalizumab/uso terapêutico
Linfócitos T Reguladores/imunologia
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Adulto
Alérgenos/imunologia
Caseínas/imunologia
Proliferação Celular
Criança
Ensaios Clínicos como Assunto
Terapia Combinada
Feminino
Histamina/metabolismo
Seres Humanos
Imunoglobulina E/imunologia
Imunoglobulina E/metabolismo
Ativação Linfocitária
Masculino
Hipersensibilidade a Leite/imunologia
Tetraspanina 30
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Allergens); 0 (Anti-Allergic Agents); 0 (CD63 protein, human); 0 (Caseins); 0 (Tetraspanin 30); 2P471X1Z11 (Omalizumab); 37341-29-0 (Immunoglobulin E); 820484N8I3 (Histamine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170418
[St] Status:MEDLINE


  9 / 879 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28408489
[Au] Autor:Fast LA; Lieber D; Lang T; Florin L
[Ad] Endereço:Department of Medical Microbiology and Hygiene, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
[Ti] Título:Tetraspanins in infections by human cytomegalo- and papillomaviruses.
[So] Source:Biochem Soc Trans;45(2):489-497, 2017 Apr 15.
[Is] ISSN:1470-8752
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Members of the tetraspanin family have been identified as essential cellular membrane proteins in infectious diseases by nearly all types of pathogens. The present review highlights recently published data on the role of tetraspanin CD151, CD81, and CD63 and their interaction partners in host cell entry by human cytomegalo- and human papillomaviruses. Moreover, we discuss a model for tetraspanin assembly into trafficking platforms at the plasma membrane. These platforms might persist during intracellular viral trafficking.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus/metabolismo
Infecções por Papillomavirus/metabolismo
Tetraspaninas/metabolismo
Proteínas Virais/metabolismo
[Mh] Termos MeSH secundário: Membrana Celular/metabolismo
Citomegalovirus/fisiologia
Seres Humanos
Modelos Moleculares
Papillomaviridae/fisiologia
Tetraspanina 24/química
Tetraspanina 24/metabolismo
Tetraspanina 28/química
Tetraspanina 28/metabolismo
Tetraspanina 30/química
Tetraspanina 30/metabolismo
Tetraspaninas/química
Internalização do Vírus
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (CD151 protein, human); 0 (CD63 protein, human); 0 (CD81 protein, human); 0 (Tetraspanin 24); 0 (Tetraspanin 28); 0 (Tetraspanin 30); 0 (Tetraspanins); 0 (Viral Proteins)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170415
[St] Status:MEDLINE
[do] DOI:10.1042/BST20160295


  10 / 879 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28396318
[Au] Autor:Zhang K; Liu J; Truong T; Zukin E; Chen W; Saxon A
[Ad] Endereço:Sixal Inc., Los Angeles, CA 90095; and kzhang@ucla.edu.
[Ti] Título:Blocking Allergic Reaction through Targeting Surface-Bound IgE with Low-Affinity Anti-IgE Antibodies.
[So] Source:J Immunol;198(10):3823-3834, 2017 May 15.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Allergic disorders have now become a major worldwide public health issue, but the effective treatment options remain limited. We report a novel approach to block allergic reactivity by targeting the surface-bound IgE of the allergic effector cells via low-affinity anti-human IgE Abs with dissociation constants in the 10 to 10 M range. We demonstrated that these low-affinity anti-IgE mAbs bind to the cell surface-bound IgE without triggering anaphylactic degranulation even at high concentration, albeit they would weakly upregulate CD203c expression on basophils. This is in contrast to the high-affinity anti-IgE mAbs that trigger anaphylactic degranulation at low concentration. Instead, the low-affinity anti-IgE mAbs profoundly block human peanut- and cat-allergic IgE-mediated basophil CD63 induction indicative of anaphylactic degranulation; suppress peanut-, cat-, and dansyl-specific IgE-mediated passive cutaneous anaphylaxis; and attenuate dansyl IgE-mediated systemic anaphylaxis in human FcεRIα transgenic mouse model. Mechanistic studies reveal that the ability of allergic reaction blockade by the low-affinity anti-IgE mAbs was correlated with their capacity to downregulate the surface IgE and FcεRI level on human basophils and the human FcεRIα transgenic mouse bone marrow-derived mast cells via driving internalization of the IgE/FcεRI complex. Our studies demonstrate that targeting surface-bound IgE with low-affinity anti-IgE Abs is capable of suppressing allergic reactivity while displaying an excellent safety profile, indicating that use of low-affinity anti-IgE mAbs holds promise as a novel therapeutic approach for IgE-mediated allergic diseases.
[Mh] Termos MeSH primário: Anafilaxia/prevenção & controle
Anticorpos Anti-Idiotípicos/imunologia
Afinidade de Anticorpos
Hipersensibilidade/prevenção & controle
Imunoglobulina E/imunologia
[Mh] Termos MeSH secundário: Anafilaxia/tratamento farmacológico
Anafilaxia/imunologia
Animais
Anticorpos Anti-Idiotípicos/administração & dosagem
Anticorpos Anti-Idiotípicos/metabolismo
Anticorpos Monoclonais/administração & dosagem
Anticorpos Monoclonais/imunologia
Anticorpos Monoclonais/metabolismo
Basófilos/imunologia
Degranulação Celular/imunologia
Citocinas/sangue
Citocinas/imunologia
Seres Humanos
Hipersensibilidade/imunologia
Imunoglobulina E/metabolismo
Camundongos
Camundongos Transgênicos
Anafilaxia Cutânea Passiva/imunologia
Diester Fosfórico Hidrolases/imunologia
Ligação Proteica
Pirofosfatases/imunologia
Tetraspanina 30/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Anti-Idiotypic); 0 (Antibodies, Monoclonal); 0 (CD63 protein, human); 0 (Cytokines); 0 (ENPP3 protein, human); 0 (Tetraspanin 30); 0 (anti-IgE antibodies); 37341-29-0 (Immunoglobulin E); EC 3.1.4.- (Phosphoric Diester Hydrolases); EC 3.6.1.- (Pyrophosphatases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1602022



página 1 de 88 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde